Ner­a­tinib CAS 698387-09-6

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

698387-09-6

Name

Ner­a­tinib

Syn­onyms

ner­a­tinib [INN] [USAN]
(2E)-N-(4-{[3-Chlor-4-(2-pyridinylmethoxy)phenyl]amino}-3-cyan-7-ethoxy-6-chinolinyl)-4-(dimethylamino)-2-butenamid [Ger­man] [ACD/IUPAC Name]
(2E)-N-(4-{[3-Chloro-4-(2-pyridinylméthoxy)phényl]amino}-3-cyano-7-éthoxy-6-quinoléinyl)-4-(diméthylamino)-2-buténamide [French] [ACD/IUPAC Name]
(2E)-N-(4-{[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino}-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-2-butenamide [ACD/IUPAC Name]
(2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
2-Bute­­namide, N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-, (2E)- [ACD/​Index Name]
698387-09-6 [RN]
HKI 272
N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide
ner­a­tinib [Span­ish] [INN]
néra­tinib [French] [INN]
ner­a­tinibum [Latin] [INN]
(2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide ner­a­tinib
(2E)-N-[4-({3-CHLORO-4-[(PYRIDIN-2-YL)METHOXY]PHENYL}AMINO)-3-CYANO-7-ETHOXYQUINOLIN-6-YL]-4-(DIMETHY­LAMINO)BUT-2-ENAM­IDE
(2E)-N-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide
(E)-4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide
(E)-N-(4-((3-chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
(E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-4-dimethylaminobut-2-enamide
(E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-4-dimethylamino-but-2-enamide
(E)-N-[4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-dimethylaminobut-2-enamide
(E)-N-[4-[[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-quinolin-6-yl]-4-dimethylamino-but-2-enamide
(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
[698387-09-6]
1110813-31-4 [RN]
1243280-86-5 [RN]
1259519-18-0 [RN]
4-Dimethy­lamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide
698387-09-6 (free base)
876310-02-0 [RN]
HKI272
HKI-272 ;HKI272 ;HKI 272
https://​www​.ebi​.ac​.uk/​c​h​e​b​i​/​s​e​a​r​c​h​I​d​.​d​o​?​c​h​e​b​i​I​d​=​C​H​E​B​I​:​6​1​397
JJH94R3PWB
MFCD09752958 [MDL num­ber]
N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide
néra­tinib
Ner­a­tinib|HKI-272
Ner­a­­tinib-d6
ner­a­tinibum
neva­tinib
UNII :JJH94R3PWB
UNII-JJH94R3P­WB
нератиниб
نيراتينيب
奈拉替尼
来那替尼

SMILES

CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4

Std­InChI

InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+

Std­InChIKey

JWN­PDZNEKVCWMY-VQHVLOKHSA-N

Mol­e­c­u­lar Formula

C₃₀H₂₉ClN₆O₃

Mol­e­c­u­lar Weight

557.043

MDL Number

MFCD09752958

Prop­er­ties

Appear­ance

White to yel­low powder

Safe­ty Data

RIDADR 

NONH for all modes of transport

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Ner­a­tinib CAS 698387-09-6

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Puri­ty

99% min

Assay (By chemical)

98%min

Water

≤1.0%

Residue on Ignition

≤1.0%

Max­i­mum sin­gle impurity

≤0.2%

Shelf Life

2 years

Stor­age

Under room tem­per­a­ture away from light

Known Appli­ca­tion

Ner­a­tinib is a tyro­sine kinase inhibitor for pro­longed adju­vant treat­ment of ear­­ly-stage HER2-pos­i­­tive breast cancer.

Gen­er­al View of Documents

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Ltd (https://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.